Tiziana Life Sciences PLC (NASDAQ:TLSA)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $5.05 and last traded at $5.10, with a volume of 2526 shares traded. The stock had previously closed at $5.95.
A number of brokerages have issued reports on TLSA. HC Wainwright restated a “buy” rating on shares of Tiziana Life Sciences in a report on Friday, December 14th. Laidlaw began coverage on Tiziana Life Sciences in a report on Monday, December 17th. They set a “buy” rating on the stock.
The firm has a market capitalization of $65.48 million and a PE ratio of -68.42.
Tiziana Life Sciences Company Profile (NASDAQ:TLSA)
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.
Featured Story: Different Types of Derivatives
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.